Distributed Manufacturing of Cell Therapies Poses a Threat to Big Pharma

As medical institutions develop the infrastructure for decentralized manufacturing of cell therapies, they are positioned to outperform big pharma’s limited success with a centralized approach to manufacturing.

A revolution is coming in the discovery, development and delivery of living medicines. This revolution is being led by well-funded, elite academic medical centers, such as the University of Pennsylvania, Fred Hutch, University College London, and other institutions across the US, Europe, South Korea, Japan and China. Almost all the approved cell and gene therapies have originated from such centers.  

Advances in manufacturing infrastructure will enable these institutions to play a more substantial role in the value chain of living medicines, from research to commercial product. Indeed, once the manufacturing infrastructure is in place, we will likely see elite medical centers and their manufacturing partners, rather than big pharma, become the major players in the development and commercialization of cell and gene therapies. 

Over 9,900 cell therapy trials are currently recruiting. No doubt many of these trials will fail, but if the past is any guide,

The post Distributed Manufacturing of Cell Therapies Poses a Threat to Big Pharma appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.


About the Author: Biotech Today

You might like